It is conceivable that some concerns about an increased risk of euglycemic ketoacidosis and acute kidney injury especially in the patients with acute illness during the treatment with SGLT2 inhibitors have influenced the therapeutic choice. Here, SLC5A2 is linked to acute kidney injury.